Overview Of In-Situ Gelling System For Diabetic Wound
Main Article Content
Abstract
The "in situ gel" system has become one of the best innovative drug delivery methods; thanks to its unique property of "Sol to Gel" transition, it aids in the prolonged and regulated release of the pharmaceuticals. An in situ gelling system is a formulation that, before entering the body, is in solution form but transforms into a gel under different physiological circumstances. Different polymers can potentially be utilized for different drug administration routes and go through in situ gel formation. In situ gelling systems have a variety of uses and benefits in modern society. The introduction to in situ gel, its mechanism, the numerous polymers utilized, and its applications are the primary topics of this paper.
Through a challenging biological process known as wound healing, damaged tissues are rebuilt and skin integrity is recovered. Insulin, a crucial component in wound healing, has been proven in numerous studies to speed up the healing of a variety of wounds in both people and animals. Despite the fact that several research have looked at how systemic insulin can treat burn wounds, relatively few have looked at how well topical insulin works. Therefore, the objective of this study was to review the information on the effects of topical insulin on both diabetic and non-diabetic wound healing. Topical insulin improves quicker wound healing through a variety of mechanisms without causing any harmful side effects, according to published animal and clinical experiments. Additionally, a number of wound dressings that deliver bioactive insulin gradually and regularly hasten the healing process. Therefore, topical insulin has been valued in the field of wound healing, and additional research is required to better understand the role of insulin in the healing of different types of wounds
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Nisha Patel, Gajanan Shinde and Rajesh KS. “Ophthalmic In situ gel”, A genesis journal Pharmagene, 2(4), 2014, 29-33.
F. Suisha, N. Kawasaki, S. Miyazaki, M. Shirakawa, K.Yamatoya, M. Sasaki, D. Attwood, Xyloglucan gels as sustained release vehicles for the intraperitoneal administration of mitomycin C. Int. J. Pharm., 172, 1998, 27–32.
Miyazaki S, Endo K, Kawasaki N, Kubo W, Watanabe H, Attwood D. “Oral sustained delivery of paracetamol from in situ gelling xyloglucan formulations”. Drug Dev Ind. Pharm., 29(2), 2003, 113-9.
Nerkar Tushar, Gujarathi Nayan A, Rane Bhushan R, Bakliwal Sunil R, Pawar S.P. “In situ gel: Novel Approch in sustained and controlled drug delivery system”. International Journal of Pharmaceutical sciences, 4(4), 2013, 1-18.
Saraswat R.1, Bhan C. S., Gaur A. “A Review on Polymers Used In In-Situ Gel Drug Delivery Systems”, 1(2), 2011.
[1] IDF Diabetes Atlas 2015, 7th ed, “International Diabetes Federation”,2015, www.diabetesatlas.org, ISBN: 978-2-930229-81-2.
F. L. Bowling, S. T. Rashid, A. J. M. Boulton, Nat. Rev. Endocrinol.2015, 11, 606; b) S. A. Eming, P. Martin, M. Tomic-Canic, Sci. Transl.Med. 2014, 6, 265sr6.
J.E. Shaw, R.A. Sicree, P.Z. Zimmet, “Global estimates of the prevalence of diabetes” for 2010 and 2030, Diabetes Res. Clin. Pract. 87 (2010) 4–14.
D.G. Armstrong, A.J.M. Boulton, S.A. Bus, “Diabetic foot ulcers and their recurrence”, N. Engl. J. Med. 376 (2017) 2367–2375.
W.J. Jeffcoate, L. Vileikyte, E.J. Boyko, D.G. Armstrong, A.J.M. Boulton, “Current challenges and opportunities in the prevention and management of diabetic foot ulcers”, Diabetes Care 41 (2018) 645–652.
Sen CK, Gordillo GM, Roy S, et al. “Human skin wounds: a major and snowballing threat to public health and the economy”. Wound Repair Regener. 2009;17(6):763–771.
Hassan WU, Greiser U, Wang W. “Role of adipose-derived stem cells in wound healing”. Wound Repair Regener. 2014;22(3):313–325.
Barrientos S, Brem H, Stojadinovic O, Tomic-canic M. “Clinical application of growth factors and cytokines in wound healing.Wound Repair Regener”. 2014;22(5):569–578.
Nie C, Yang D, Xu J, Si Z, Jin X, Zhang J. “Locally administered adipose-derived stem cells accelerate wound healing through differentiation and vasculogenesis”. Cell Transplant. 2011;20(2):205–216.
Oryan A, Alemzadeh E. “Effects of insulin on wound healing: a review of animal and human evidences”. Life Sci. 2017;174:59–67.
Wang L, Yang B, Jiang H, et al. “The molecular mechanism study of insulin in promoting wound healing under high-glucose conditions”. J Cell Biochem. 2019;120(9):16244–16253.
Kakanj P, Moussian B, Gronke S, et al. “Insulin and TOR signal in parallel through FOXO and S6K to promote epithelial wound healing”. Nat Commun. 2016;7:12972.
Zhao L, Niu L, Liang H, Tan H, Liu C, Zhu F. “pH and glucose dual-responsive injectable hydrogels with insulin and fibroblasts as bioactive dressings for diabetic wound healing”. ACS Appl Mater Interfaces. 2017;9(43):37563–37574.
Vatankhah N, Jahangiri Y, Landry GJ, Moneta GL, Azarbal AF. “Effect of systemic insulin treatment on diabetic wound healing”. Wound Repair Regener. 2017;25(2):288–291.
Sridharan K, Sivaramakrishnan G. “Efficacy of topical insulin in wound healing: a preliminary systematic review and meta-analysis of randomized controlled trials”. Wound Repair Regener. 2017;25(2):279–287.
Hrynyk M, Neufeld RJ. “Insulin and wound healing. Burns”. 2014;40 (8):1433–1446.
Goole J, Vanderbist F, Aruighi K. “Development and Evaluation of new multiple-unit- Levodopa sustained release floating dosage forms”. Int J Pharm 2007:334:35-41.
Sharma S, Pawar A. “Low density multiparticulate system for pulasatile release of Meloxicam”. Int J.Pharm 2006:313:150-58.
Miyazaki S, Kawasaki N. “Comparison of in situ gelling formulations for the oral delivery of cimetidine”. Int J Pharm, 220, 2001, 161-8.
Kokate C.K., Purohit A. P., Gokhale S.B. “Pharmacognocy. 14th Ed. Published by Nirali Prakashan”, 137, 2008,141,146,152.
Davies N.M., Farr S.J., Hadgraft J., Kellaway L.W. “Evaluation of mucoadhesive polymers in ocular drug delivery”. I. Viscous solutions, Pharm. Res., 8(8), 1991, 1039–1043.
Shastri DH, Patel LD, “Novel alternative to ocular drug delivery system”: Hydrogel, Ind J Pharma Res, 2010; 2: 1-13.
Miyazaki S, Suisha F, Kawasaki N, Shirakawa M, Yamatoya K, Attwood K, “Thermally reversible xyloglucan gels as vehicles for rectal drug delivery”, J Control Rel, 56, 1998, 75-83.
Sechoy O, Tissie G, Sebastian C, Maurin F, Driot JY, Trinquand C. “A new long acting ophthalmic formulation of carteolol containing Alginic acid”. Int J Pharm, 207, 2000,109-16.
Grant G.T., Morris E.R., Rees D.A., Smith P.J.C., Thom D. “Biological interactions between polysaccharides and divalent cations”: The egg box model. FEBS Lett., 32, 1973,195-198.
Al-Shamklani A, Bhakoo M, Tuboku MA, Duncan R. “Evaluation of the biological properties of alginates and gellan and xanthan gum. Proc Int Symp Control Release Bioact Mater”, 18, 1991, 213-4.
Chenite A, Chaput C, Wang D, Combes C, Buschmann MD, Hoemann CD et al. “Novel injectable solution of chitosan form biodegradable gels in situ”. Biomaterials, 21, 2000,2155-61.
Nirmal H.B, Bakliwal S.R., Pawar S.P, “In-Situ gel: New trends in Controlled and Sustained Drug Delivery System”. Int J Pharm Tech Research, 2010;2(2), 1398-408.
Thakur RR, Sharma M. “An insight to ophthalmic in situ gel an overview”. Int Res J Pharm,2012; 3(3):16-21
Available from “http:www.slideshare.net/shreeraj9183/in situ-gel-delivery system”. [Last accessed on January 2016 25 1].
Sterile ophthalmic gel forming solution, Timoptic- XE;, 0.25% and 0.5%, (Timolol maleate ophthalmic gel forming solution), Merck and Company Inc. NJ08889: Whitehouse Station, USA.
40. Ramesh CR, Zentner GM, Jeong B. Macro med, Inc. “Biodegradable low molecular weight triblock poly (lactideco- glycolide) polyethylene glycolcopolymers having reverse thermal gelation properties”. US patent 6201072. 2001.
B. Farhdihosseinabadi, M. Salimi, B. Kazemi, H. Ghanbarian, M. Mozafari and H. Niknejad, “Med.Hypotheses”, 2020, 134, 109389.
Z. Xu, S. Han, Z. Gu and J. Wu, Adv. “Healthcare Mater”.,2020, 9, 1901502.
S. A. Eming, P. Martin and M. Tomic-Canic, Sci. Transl. Med., 2014, 6, 265sr266 265sr266.
B. K. Sun, Z. Siprashvili and P. A. Khavari, Science, 2014,346, 941–945.
S. A. Shah, M. Sohail, S. Khan, M. U. Minhas, M. de Matas, V. Sikstone, Z. Hussain, M. Abbasi and M. Kousar,Int. J. Biol. Macromol., 2019, 139, 975–993.
M. Otero-Viñas and V. Falanga, “in The Diabetic Foot, Springe”r, 2018, pp. 257–264.
V. Falanga, Lancet, 2005, 366, 1736–1743.
D. Skuratovskaia, M. Vulf, O. Khaziakhmatova, V. Malashchenko, A. Komar, E. Shunkin, V. Shupletsova,A. Goncharov, O. Urazova and L. Litvinova, Biomedicines,2020, 8(10), 400.
T. A. Wynn and K. M. “Vannella, Immunity”, 2016, 44, 450–462.
Wu, S. C., Jensen, J. L., Weber, A. K., Robinson, D. E., & Armstrong, D. G.(2008). “Use of pressure offloading devices in diabetic foot ulcers”: Do we practice what we preach? Diabetes Care, 31(11), 2118–2119.
Mosti, G., Iabichella, M. L., Picerni, P., Magliaro, A., & Mattaliano, V. (2005).”The debridement of hard to heal leg ulcers by means of a new device based on Fluidjet technology”. International Wound Journal, 2(4),307–314.
Sherman, R. A. “Mechanisms of maggot-induced wound healing:What do we know, and where do we go from here?” Evidence-based Complementary and Alternative Medicine, 2014, 1–13.
Enoch, S., & Harding, K. (2003). “Wound bed preparation: The science behind the removal of barriers to healing. Wounds”, 15(7), 213–229.
Liu, W.-L., Jiang, Y.-L., Wang, Y.-Q., Li, Y.-X., & Liu, Y.-X. (2017). “Combined debridement in chronic wounds”: A literature review. Chinese Nursing Research, 4(1), 5–8.
Boateng, J. S., Matthews, K. H., Stevens, H. N., & Eccleston, G. M. (2008). “Wound healing dressings and drug delivery systems”: A review. Journal of Pharmaceutical Sciences, 97(8), 2892–2923.
Rivera, A. E., & Spencer, J. M. (2007). “Clinical aspects of full-thickness wound healing”. Clinics in Dermatology, 25(1), 39–48.
S. Cohen, E. Lobel, A. Trevgoda, Y. Peled. “A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye”. J. Control, Release. 1997;44 201-208.
B. Srividya, R.M. Cardoza, P.D. Amin. “Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system”. J. Control Release. 2001;73: 205-211.
S. Miyazaki, N. Kawasaki, K. Endo, D. Attwood “Oral sustained delivery of theophylline from thermally reversible xyloglucan gels in rabbits”. J. Pharm. Pharmacol. 2001; 53: 1185-1191.
S. Miyazaki, S.Suzuki, N. Kawasaki, K. Endo, Takahashi, D. Attwood. “In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride”.Int. J. Pharm. 2001; 229: 29-36.
Hoffman A., Stepensky D. (1999) “Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy”. Crit. Rev. Ther. Drug carrier Syst. 16:571-639